Watson to market cancer drug
- Share via
From Times Wire Services
Watson Pharmaceuticals Inc. won clearance to sell the first generic version of Pfizer Inc.’s cancer drug Camptosar.
The Food and Drug Administration approved Watson’s generic irinotecan hydrochloride after patents on the brand-name drug expired. Corona-based Watson said it was entitled to 180 days of market exclusivity before the FDA could approve another generic.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
